治疗性单克隆抗体的研发：基于在研项目的分析
Research and development of therapeutic mAbs: An analysis based on pipeline projects.
作者信息
Geng Xiaomei, Kong Xiangjun, Hu Hao, Chen Jiayu, Yang Fengqing, Liang Hongyu, Chen Xin, Hu Yuanjia
机构信息
a State Key Laboratory of Quality Research in Chinese Medicine; Institute of Chinese Medical Sciences; University of Macau ; Macau SAR , China.
b College of Medical Bioengineering and Faculty of Life Sciences; Chongqing University ; Chongqing , China.
出版信息
Hum Vaccin Immunother. 2015;11(12):2769-76. doi: 10.1080/21645515.2015.1074362.
Abstract
As the subject of active research and development (R&D) in recent decades, monoclonal antibodies have emerged among the major classes of therapeutic agents for treatment of many human diseases, especially cancers, infections, and immunological disorders. This article surveys the landscape of R&D projects of therapeutic monoclonal antibodies (mAbs), which are mostly used for disease immunotherapy, from a number of perspectives, including therapeutic indications, development phases, participants, and citation of related patents. The results of this research can be used as a reference resource for pharmaceutical researchers, investors, and policymakers in the field of therapeutic mAbs.
摘要
作为近几十年来积极研发的对象，单克隆抗体已成为治疗多种人类疾病，尤其是癌症、感染和免疫紊乱的主要治疗药物类别之一。本文从治疗适应症、开发阶段、参与者以及相关专利引用等多个角度，对主要用于疾病免疫治疗的治疗性单克隆抗体（mAb）的研发项目情况进行了综述。本研究结果可供治疗性单克隆抗体领域的药物研究人员、投资者和政策制定者参考。
相似文献
1
Research and development of therapeutic mAbs: An analysis based on pipeline projects.治疗性单克隆抗体的研发：基于在研项目的分析
Hum Vaccin Immunother. 2015;11(12):2769-76. doi: 10.1080/21645515.2015.1074362.
2
Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer.植物生产的单克隆抗体作为癌症的免疫疗法。
Biomed Res Int. 2020 Aug 24;2020:3038564. doi: 10.1155/2020/3038564. eCollection 2020.
3
Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.使用偶联和非偶联单克隆抗体进行人类癌症检测与免疫治疗。
Anticancer Res. 1996 Mar-Apr;16(2):661-74.
4
Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.癌症的靶向治疗：单克隆抗体和纳米抗体的应用
Hum Antibodies. 2009;18(3):81-100. doi: 10.3233/HAB-2009-0204.
5
Therapeutic monoclonal antibodies: trends in development and approval in the US.治疗性单克隆抗体：美国的研发与获批趋势
Curr Opin Mol Ther. 2002 Apr;4(2):110-8.
6
Future prospects of monoclonal antibodies as magic bullets in immunotherapy.单克隆抗体作为免疫疗法中神奇子弹的未来前景。
Hum Antibodies. 2013;22(1-2):9-13. doi: 10.3233/HAB-130266.
7
Monoclonal antibodies in clinical hematology and oncology.临床血液学与肿瘤学中的单克隆抗体
Curr Opin Investig Drugs. 2007 Dec;8(12):996-1001.
8
Challenges and opportunities for monoclonal antibody therapy in veterinary oncology.单克隆抗体疗法在兽医肿瘤学中的挑战与机遇
Vet J. 2016 Dec;218:40-50. doi: 10.1016/j.tvjl.2016.11.005. Epub 2016 Nov 16.
9
Production of monoclonal antibodies in plants for cancer immunotherapy.用于癌症免疫治疗的植物源单克隆抗体的生产。
Biomed Res Int. 2015;2015:306164. doi: 10.1155/2015/306164. Epub 2015 Oct 15.
10
Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6 antibody industrial symposium, June 25-26, 2018, Montpellier, France.MAbs 靶点：发现和验证的创新方法，LabEx MAbImprove 抗体工业研讨会，2018 年 6 月 25-26 日，法国蒙彼利埃。
MAbs. 2019 Jul;11(5):812-825. doi: 10.1080/19420862.2019.1612691. Epub 2019 May 16.
引用本文的文献
1
Monoclonal antibodies in neuro-ophthalmology.神经眼科学中的单克隆抗体
Saudi J Ophthalmol. 2024 Mar 29;38(1):13-24. doi: 10.4103/sjopt.sjopt_256_23. eCollection 2024 Jan-Mar.
2
Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry.推动癌症免疫治疗的下一步发展：从基于抗体的双特异性药物到多特异性药物，生物共轭化学的作用不断演变。
RSC Chem Biol. 2021 Oct 22;3(2):140-169. doi: 10.1039/d1cb00082a. eCollection 2022 Feb 9.
3
A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents.肝细胞癌（HCC）前沿治疗方法综述：专利视角。
Int J Med Sci. 2021 Jun 18;18(14):3066-3081. doi: 10.7150/ijms.59930. eCollection 2021.
4
Technological Advancements in Monoclonal Antibodies.单克隆抗体的技术进展。
ScientificWorldJournal. 2021 Feb 10;2021:6663708. doi: 10.1155/2021/6663708. eCollection 2021.
5
The pharmacology and therapeutic applications of monoclonal antibodies.单克隆抗体的药理学和治疗应用。
Pharmacol Res Perspect. 2019 Dec;7(6):e00535. doi: 10.1002/prp2.535.
6
Strategies for Selecting Membrane Protein-Specific Antibodies using Phage Display with Cell-Based Panning.利用基于细胞淘选的噬菌体展示技术筛选膜蛋白特异性抗体的策略
Antibodies (Basel). 2017 Aug 5;6(3):10. doi: 10.3390/antib6030010.
7
Research and development of mAb drugs in China: a look from policy perspectives.中国单抗药物的研发：政策视角的观察。
Hum Vaccin Immunother. 2019;15(11):2695-2705. doi: 10.1080/21645515.2019.1605809. Epub 2019 May 22.
8
Quantification of residual AEBSF-related impurities by reversed-phase liquid chromatography.反相液相色谱法定量分析残留的 AEBSF 相关杂质。
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 May 15;1116:19-23. doi: 10.1016/j.jchromb.2019.03.022. Epub 2019 Mar 20.
9
Impact of a Heat Shock Protein Impurity on the Immunogenicity of Biotherapeutic Monoclonal Antibodies.热休克蛋白杂质对治疗性单克隆抗体免疫原性的影响。
Pharm Res. 2019 Feb 15;36(4):51. doi: 10.1007/s11095-019-2586-7.
10
Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries.免疫噬菌体展示文库衍生的单克隆抗体和抗体样片段。
Adv Exp Med Biol. 2017;1053:99-117. doi: 10.1007/978-3-319-72077-7_6.
本文引用的文献
1
Building better monoclonal antibody-based therapeutics.开发更优的基于单克隆抗体的疗法。
Nat Rev Cancer. 2015 Jun;15(6):361-70. doi: 10.1038/nrc3930.
2
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.基于肿瘤抗原靶向单克隆抗体的免疫治疗：为长期抗肿瘤免疫的发展协调联合策略。
Oncoimmunology. 2014 Dec 13;3(9):e955684. doi: 10.4161/21624011.2014.955684. eCollection 2014 Oct.
3
The future of immune checkpoint therapy.免疫检查点疗法的未来。
Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.
4
Development of monoclonal antibodies in China: overview and prospects.中国单克隆抗体的发展：概述与展望。
Biomed Res Int. 2015;2015:168935. doi: 10.1155/2015/168935. Epub 2015 Feb 25.
5
Dendritic-cell-based technology landscape: Insights from patents and citation networks.基于树突状细胞的技术全景：来自专利和引文网络的见解
Hum Vaccin Immunother. 2015;11(3):682-8. doi: 10.1080/21645515.2015.1008857.
6
Targeting HER2 for the treatment of breast cancer.针对乳腺癌的 HER2 靶向治疗。
Annu Rev Med. 2015;66:111-28. doi: 10.1146/annurev-med-042513-015127.
7
The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.治疗用抗体工程的现状与展望：聚焦糖基工程技术
J Pharm Sci. 2015 Mar;104(3):930-41. doi: 10.1002/jps.24316. Epub 2015 Jan 12.
8
The history of monoclonal antibody development - Progress, remaining challenges and future innovations.单克隆抗体的发展历程——进展、尚存挑战及未来创新
Ann Med Surg (Lond). 2014 Sep 11;3(4):113-6. doi: 10.1016/j.amsu.2014.09.001. eCollection 2014 Dec.
9
Case studies on clinical evaluation of biosimilar monoclonal antibody: scientific considerations for regulatory approval.生物类似单克隆抗体临床评估的案例研究：监管批准的科学考量
Biologicals. 2015 Jan;43(1):1-10. doi: 10.1016/j.biologicals.2014.11.002. Epub 2014 Nov 29.
10
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.克服HER2过表达乳腺癌中曲妥珠单抗耐药的策略：聚焦于临床试验的新数据。
BMC Med. 2014 Aug 12;12:132. doi: 10.1186/s12916-014-0132-3.
Zotero 插件